dr well semaglutide (Wegovy) is associated with a 41% reduction in the risk for major adverse cardiovascular events (MACEs) within 6 months of initiation — before patients achieve substantial weight loss or reach Months Supply:1 Month Laboratory Chemical Read all about GLP-1

dr well semaglutide (Wegovy) is associated with a 41% reduction in the risk for major adverse cardiovascular events (MACEs) within 6 months of initiation — before patients achieve substantial weight loss or reach Months Supply:1 Month Laboratory Chemical Read all about GLP-1

Read all about GLP-1 in this week's newsletter. link in bio.

The lower figure includes everyone who joined the trial, whether or not they completed it or stayed on the medication

Laboratory Chemical

Months Supply:1 Month

Ziltivekimab, a new monoclonal antibody directed against IL-6, has been specifically designed for patients with atherosclerosis and high cardiovascular risk and is being evaluated both in patients with atherosclerosis and CKD and in patients with HFpEF [20–22]